“What’s Wrong With Canadian Healthcare?” shows that Bismarckian healthcare systems, in which there is market competition amongst insuring entities (no/low wait times, access to novel drugs, and low costs) outperform Beveridge systems that have state monopolies in financing (wait times, limited drug access, and higher costs). For Canada, with its Beveridge system, this means that Canadian healthcare lacks adequate capacity for its population, does not receive value-for-money in financing and purchasing physician and hospital services, and has taken an anti-business stance that prohibits market competition to lower costs and improve quality.